Drugs such as glucagon-like peptide-1 (GLP-1) agonists, pioglitazone, and sodium-dependent glucose transporter 2 (SGLT2) inhibitors are currently available for the treatment of obesity and type 2 diabetes mellitus(T2DM), but there is currently no FDA-approved drug therapy for NASH (3). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.